Intravascular donor monocytes play a central role in lung transplant ischaemia-reperfusion injury
File(s)thoraxjnl-2016-208977.full.pdf (1.89 MB)
Published version
Author(s)
Type
Journal Article
Abstract
Rationale Primary graft dysfunction in lung transplant recipients derives from the initial, largely leukocyte-dependent, ischaemia-reperfusion injury. Intravascular lung-marginated monocytes have been shown to play key roles in experimental acute lung injury, but their contribution to lung ischaemia-reperfusion injury post transplantation is unknown.
Objective To define the role of donor intravascular monocytes in lung transplant-related acute lung injury and primary graft dysfunction.
Methods Isolated perfused C57BL/6 murine lungs were subjected to warm ischaemia (2 hours) and reperfusion (2 hours) under normoxic conditions. Monocyte retention, activation phenotype and the effects of their depletion by intravenous clodronate-liposome treatment on lung inflammation and injury were determined. In human donor lung transplant samples, the presence and activation phenotype of monocytic cells (low side scatter, 27E10+, CD14+, HLA-DR+, CCR2+) were evaluated by flow cytometry and compared with post-implantation lung function.
Results In mouse lungs following ischaemia-reperfusion, substantial numbers of lung-marginated monocytes remained within the pulmonary microvasculature, with reduced L-selectin and increased CD86 expression indicating their activation. Monocyte depletion resulted in reductions in lung wet:dry ratios, bronchoalveolar lavage fluid protein, and perfusate levels of RAGE, MIP-2 and KC, while monocyte repletion resulted in a partial restoration of the injury. In human lungs, correlations were observed between pre-implantation donor monocyte numbers/their CD86 and TREM-1 expression and post-implantation lung dysfunction at 48 and 72 hours.
Conclusions These results indicate that lung-marginated intravascular monocytes are retained as a ‘passenger’ leukocyte population during lung transplantation, and play a key role in the development of transplant-associated ischaemia-reperfusion injury.
Objective To define the role of donor intravascular monocytes in lung transplant-related acute lung injury and primary graft dysfunction.
Methods Isolated perfused C57BL/6 murine lungs were subjected to warm ischaemia (2 hours) and reperfusion (2 hours) under normoxic conditions. Monocyte retention, activation phenotype and the effects of their depletion by intravenous clodronate-liposome treatment on lung inflammation and injury were determined. In human donor lung transplant samples, the presence and activation phenotype of monocytic cells (low side scatter, 27E10+, CD14+, HLA-DR+, CCR2+) were evaluated by flow cytometry and compared with post-implantation lung function.
Results In mouse lungs following ischaemia-reperfusion, substantial numbers of lung-marginated monocytes remained within the pulmonary microvasculature, with reduced L-selectin and increased CD86 expression indicating their activation. Monocyte depletion resulted in reductions in lung wet:dry ratios, bronchoalveolar lavage fluid protein, and perfusate levels of RAGE, MIP-2 and KC, while monocyte repletion resulted in a partial restoration of the injury. In human lungs, correlations were observed between pre-implantation donor monocyte numbers/their CD86 and TREM-1 expression and post-implantation lung dysfunction at 48 and 72 hours.
Conclusions These results indicate that lung-marginated intravascular monocytes are retained as a ‘passenger’ leukocyte population during lung transplantation, and play a key role in the development of transplant-associated ischaemia-reperfusion injury.
Date Issued
2018-03-19
Date Acceptance
2017-03-10
Citation
Thorax, 2018, 73 (4), pp.350-360
ISSN
1468-3296
Publisher
BMJ Publishing Group
Start Page
350
End Page
360
Journal / Book Title
Thorax
Volume
73
Issue
4
Copyright Statement
© 2017 Article author (or their employer) 2017. Produced by BMJ Publishing Group Ltd (& BTS) under licence. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
Sponsor
Wellcome Trust
Royal Brompton & Harefield NHS Foundation Trust
Cystic Fibrosis Trust
Cystic Fibrosis Research Trust - HRF
Royal Brompton & Harefield NHS Foundation Trust
Wellcome Trust
Grant Number
097471/Z/11/Z
WSSA_P41866
WSSA_P40127
MXZ146459
N/A
Subjects
Innate Immunity
Lung Transplantation
Macrophage Biology
Harefield POPSTAR investigators
1103 Clinical Sciences
Respiratory System
Publication Status
Published
Date Publish Online
2017-04-07